



PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 58345

Title: Overexpression of CD155 associated with PD-1 and PD- Y expression on immune cells, rather than tumor cells in microenvironment of breast cancer

Reviewer's code: 02857993

Position: Peer Reviewer

Academic degree: FRCPA, MD, PhD

Professional title: Doctor, Professor

Reviewer's Country/Territory: Australia

Author's Country/Territory: China

Manuscript submission date: 2020-07-18

Reviewer chosen by: Jin-Lei Wang

Reviewer accepted review: 2020-08-13 11:54

Reviewer performed review: 2020-08-17 08:30

Review time: 3 Days and 20 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

CD155 is one ligand of T cell immunoglobulin and ITIM domain expressed in various cell types, including antigen-presenting cells and tumor cells and the interaction limits cell function through feedback inhibition. Normal tissues have no or low expression of CD155 but malignancies have upregulated expression, which plays a key role in tumor cell invasion and migration. PD-1 is an immune checkpoint molecule and the interaction inhibits biological functions of effector T-cells. PD-1 expression on breast cancer TILs was related with different clinicopathological characteristics. However, whether the exhausted phenotypes of effector TILs and PD-L1 is related to the CD155 expression on breast cancer has not been reported. In this study, the authors investigated the distribution of CD155 expression and their relationship with PD-L1 and phenotypes of exhausted CD4⁺ and CD8⁺ effector TILs to illustrate the effect of CD155 expression on immune microenvironment of breast cancer patients. Overall, this study is well designed and the manuscript is well written. Some minor comments: 1. Manuscript requires a minor editing. 2. The data in tables are very interesting, however, please check the tables again, and edit it. Some of the phrase are too redundancy. 3. A background is missing for the abstract.



PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 58345

Title: Overexpression of CD155 associated with PD-1 and PD- Y expression on immune cells, rather than tumor cells in microenvironment of breast cancer

Reviewer’s code: 02856659

Position: Peer Reviewer

Academic degree: FEBS, MBBS, PhD

Professional title: Associate Professor, Research Scientist, Senior Researcher

Reviewer’s Country/Territory: Swaziland

Author’s Country/Territory: China

Manuscript submission date: 2020-07-18

Reviewer chosen by: Jin-Lei Wang

Reviewer accepted review: 2020-08-13 11:54

Reviewer performed review: 2020-08-17 08:32

Review time: 3 Days and 20 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

This manuscript of CD155 and breast cancer is generally very interesting. A minor editing is required before final publication.